12 results about "Inflammatory dermatosis" patented technology

The invention provides a pharmaceutical composition for treating inflammatory skin diseases, and particularly relates to an O / W cream containing trifarotene. The pharmaceutical composition provided by the invention has proper viscosity and elasticity, and the trifarotene composition preferably contains diethylene glycol monoethyl ether. The pharmaceutical composition can be directly applied to skin.

The present disclosure relates to a novel ALPK1 inhibitor of formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, atropisomer, stable isotope variant, prodrug, or crystalline form thereof. The disclosure also relates to pharmaceutical compositions comprising said novel ALPK1 inhibitors, and their use in the treatment of inflammatory related diseases, such as ROSAH syndrome, inflammatory bowel disease (IBD), NASH, gout, diabetes, chronic kidney disease, pancreatitis, Kawasaki disease, inflammatory skin disease, and neurodegenerative diseases including Alzheimer's disease.

The present invention is directed to compositions and methods for ameliorating symptoms associated with inflammatory skin disorders involving applying a synergistic blend of plant-based actives containing: (1) a synergistic blend of at least: (a) Calendula officinalis stem cell extract; (b) Symphytum officinale extract; (c) a biotech-derived Haberlea rhodopensis extract; and (d) Padina pavonica thallus extract; and (2) at least one skin protectant active ingredient.

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic / injured area).

Disclosed is a substance which down-regulates the activity of a MAST gene, or the activity of a transcription or translation product of a MAST gene, for use in the prevent and / or treatment of an inflammatory skin condition in a mammalian subject.

The present invention is directed to compositions and methods for ameliorating symptoms associated with inflammatory skin disorders involving applying a synergistic blend of plant-based actives containing: (1) a synergistic blend of at least: (a) Calendula officinalis stem cell extract; (b) Symphytum officinale extract; (c) a biotech-derived Haberlea rhodopensis extract; and (d) Padina pavonica thallus extract; and (2) at least one skin protectant active ingredient.

The invention discloses an AC (at) Mg / Ce-UiO nano particle, a preparation method thereof and application of the nano particle in medicines for treating inflammatory dermatosis, and belongs to the technical field of biological medicines. Adenylate cyclase (AC) is encapsulated in situ in an Mg / Ce-UiO metal organic framework designed by defect engineering, and a unique structure brings dual treatment strategies: the encapsulated AC catalyzes pro-inflammatory ATP to be converted into anti-inflammatory cAMP to restore balance; defective Mg / Ce-UiO simulates SOD (superoxide dismutase) and CAT (catalase) to remove excessive ROS. The nanoparticles can down-regulate the expression of various inflammatory factors and pruritus mediators, inhibit the excessive proliferation of keratinocytes and reduce the infiltration of immune memory T cells. Therefore, the effects of treating inflammatory skin disease skin lesion, remarkably relieving itching and preventing relapse are achieved. The preparation method is simple and easy for large-scale production. The invention introduces a reform mode to the treatment of inflammatory dermatosis, provides a curative strategy, establishes a multifunctional treatment framework, and is expected to be suitable for more extensive inflammation and autoimmune diseases.

The invention discloses a compound tincture for treating inflammatory skin diseases and a preparation method of the compound tincture. The compound tincture is prepared from the following raw materials in percentage by weight: 0.02 to 0.06 percent of fluocinonide, 0.75 to 1.75 percent of chloramphenicol, 3 to 7 percent of salicylic acid, 0.05 to 0.15 percent of nano antibacterial particles, 1 to 3 percent of borneol, 6 to 10 percent of propylene glycol and the balance of water for injection. Compared with a compound fluocinonide tincture, the compound tincture has obvious effects in the aspects of relieving the severity of eczema, relieving the degree of pruritus and improving the quality of life in the clinical treatment process, and the total effective rate reaches 82-95.6%; compared with clindamycin hydrochloride gel, the total effective rate is high in the acne treatment period, the recurrence rate is low, and the untoward effect occurrence rate is not different; the relapse tincture disclosed by the invention has a remarkable and lasting curative effect on acne and eczema and a relatively small side effect, and is simple in preparation method, low in cost, remarkable in clinical curative effect and worthy of clinical popularization.

The invention relates to a pharmaceutical composition for treating inflammatory dermatosis and a preparation method thereof, and the preparation method comprises the following steps: 1) mixing oleyl alcohol, medium chain triglyceride, propylene glycol, hexadecanol and octadecanol, and heating to 65-75 DEG C to form an oil phase; adding pimerolimus and glyceryl monostearate and glyceryl distearate, and stirring to obtain an oil phase; 2) adding anhydrous citric acid, sodium hydroxide and benzyl alcohol into water, and heating to 65-75 DEG C for dissolving; adding cetostearyl sodium sulfate, and stirring to obtain a water phase; 3) pouring the oil phase into the water phase, maintaining the emulsification temperature at 65-75 DEG C, homogenizing and stirring to form an emulsion; and 4) filling and packaging. Wherein the mixed solution is subjected to homogenization treatment at the speed of 3000rpm for 10 minutes, homogenization is stopped, stirring is continued for 5 minutes at the speed of 25rpm, and the mixed solution is subjected to homogenization treatment at the speed of 3000rpm for 10 minutes again. The ratio of the humectant to the thickening agent in the pharmaceutical composition is creatively adjusted, so that the treatment efficiency of the ointment is greatly improved, and the user experience in the application process of the ointment is also remarkably improved.

The invention belongs to the field of drugs for inflammatory dermatosis, and discloses an application of myrcene in preparation of drugs for inflammatory dermatosis, which comprises the following steps: combining a mouse AD model (DNCB) with human epidermal keratinocytes (NHEK) and mouse macrophages (RAW264.7); the improvement effect of the MYR is evaluated by adopting histology and immunofluorescence technologies; by integrating transcriptomics and proteomics analysis, the molecular mechanism of MYR for relieving AD symptoms is clarified, and the causal relationship is verified by using a pharmacological inhibitor. The conclusion of the invention is as follows: Myrcene alleviates AD sample inflammation by inhibiting FAK / Src-YAP / TAZ axis. A repeatable mechanism framework is established by the data, and the natural monoterpenoids are associated with biomechanical-nuclear signal transduction and innate immune regulation in AD.

The invention discloses a method for constructing an NPPK mouse model based on a CRISPR / Cas9 technology and application of the NPPK mouse model, and belongs to the technical field of genetic engineering and disease model construction. The preparation method comprises the following steps: performing targeted knockout on a mouse Serpina12 gene through a CRISPR / Cas9 gene editing technology to obtain a Serpina12 gene-deficient mouse; an acetone-diethyl ether mixed solution (formed by mixing acetone and diethyl ether according to the volume ratio of 1: 1) and double distilled water are sequentially and externally applied to the skin surface of the Serpina12 gene defect mouse, and the NPPK mouse model is obtained. The method has the characteristics of simplicity and convenience in operation, high efficiency and stable phenotype, and the NPPK mouse model obtained by the method can be used for researching inflammatory keratotic dermatosis and screening drugs for treating NPPK or IL-17 related inflammatory dermatosis.

Use of antisense thiomorpholino oligonucleotides to treat, prevent, or ameliorate the progression of inflammatory skin diseases or conditions such as psoriasis. Specifically, thiomorpholino¬ containing ASOs that target pre-mRNAs associated with inflammatory skin diseases or conditions such as psoriasis.